227 related articles for article (PubMed ID: 36927688)
21. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
22. TFEB drives mTORC1 hyperactivation and kidney disease in Tuberous Sclerosis Complex.
Alesi N; Khabibullin D; Rosenthal DM; Akl EW; Cory PM; Alchoueiry M; Salem S; Daou M; Gibbons WF; Chen JA; Zhang L; Filippakis H; Graciotti L; Miceli C; Monfregola J; Vilardo C; Morroni M; Di Malta C; Napolitano G; Ballabio A; Henske EP
Nat Commun; 2024 Jan; 15(1):406. PubMed ID: 38195686
[TBL] [Abstract][Full Text] [Related]
23. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
24. [
Verwer EE; Kavanagh TR; Mischler WJ; Feng Y; Takahashi K; Wang S; Shoup TM; Neelamegam R; Yang J; Guehl NJ; Ran C; Massefski W; Cui Y; El-Chemaly S; Sadow PM; Oldham WM; Kijewski MF; El Fakhri G; Normandin MD; Priolo C
Clin Cancer Res; 2018 Dec; 24(23):5925-5938. PubMed ID: 30054282
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
[TBL] [Abstract][Full Text] [Related]
26. Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells.
Alayev A; Sun Y; Snyder RB; Berger SM; Yu JJ; Holz MK
Cell Cycle; 2014; 13(3):371-82. PubMed ID: 24304514
[TBL] [Abstract][Full Text] [Related]
27. Bcat1 is controlled by Tsc2/mTORC1 pathway at expression levels and its deficiency together with Bcat2 inactivation suppresses the growth of a Tsc2
Nishikawa K; Mezawa Y; Kobayashi T
Genes Cells; 2023 Jun; 28(6):447-456. PubMed ID: 36965015
[TBL] [Abstract][Full Text] [Related]
28. Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent.
Parkhitko A; Myachina F; Morrison TA; Hindi KM; Auricchio N; Karbowniczek M; Wu JJ; Finkel T; Kwiatkowski DJ; Yu JJ; Henske EP
Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12455-60. PubMed ID: 21746920
[TBL] [Abstract][Full Text] [Related]
29. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
30. Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.
Liu F; Lunsford EP; Tong J; Ashitate Y; Gibbs SL; Yu J; Choi HS; Henske EP; Frangioni JV
PLoS One; 2012; 7(6):e38589. PubMed ID: 22719903
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
32. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
[TBL] [Abstract][Full Text] [Related]
33. TSC2 epigenetic defect in primary LAM cells. Evidence of an anchorage-independent survival.
Lesma E; Ancona S; Sirchia SM; Orpianesi E; Grande V; Colapietro P; Chiaramonte E; Di Giulio AM; Gorio A
J Cell Mol Med; 2014 May; 18(5):766-79. PubMed ID: 24606538
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
35. Lymphangioleiomyomatosis Association with Underlying Genotype in Patients with Tuberous Sclerosis Complex.
Tian X; Glass JE; Kwiatkowski DJ; Towbin AJ; Li Y; Sund KL; Krueger DA; Franz DN; McCormack FX; Gupta N
Ann Am Thorac Soc; 2021 May; 18(5):815-819. PubMed ID: 33171065
[No Abstract] [Full Text] [Related]
36. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
[TBL] [Abstract][Full Text] [Related]
37. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
Liu HJ; Krymskaya VP; Henske EP
Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
